Abstract
The efficacy of doxazosin monotherapy inchronic non-bacterial prostatitis wasinvestigated in terms of urinary symptom, painand quality of life assessment versus placebo.A total of 60 men with chronic non-bacterialprostatitis were randomised to daily supplementof 4 mg doxazosin or a placebo, for 3 months.International Prostate Symptom Score (IPSS)questionnaire was self administered at theentry and at 3 months after the cessation ofthe treatment. In addition, patients were askedto complete 2-item questionnaire on painrelated symptoms of chronic prostatitis.Quality of life was assessed with a single itemincluded in IPSS.Three months after cessation of the treatmentthere was a significant difference between theoverall mean IPSS, pain and quality of lifescores of the two groups in favour ofα-blocking agent use (p = 0.001, p <0.001 and p < 0.001, respectively). Inpatients undergone doxazosin treatment;symptom, pain and quality of life statusrevealed 32.94 ± 5.27%, 36.57 ± 5.67%and 36.78 ± 4.75% overall improvement,respectively. IPSS appeared to be a valuabletool in assessing treatment outcome of chronicnon-bacterial prostatitis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barry MJ, Fowler FJ Jr, O'Leary MP et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992; 148: 1549–1557.
Cockett ATK, Aso Y, Denis L et al. Recommendations of the International Consensus Committee concerning: (1) Prostate symptom score (I-PSS) and quality of life assessment. (2) Diagnostic work-up of patients presenting with symptoms suggestive of prostatism. (3) Standardization of the evaluation of treatment modalities. (4) BPH treatment recommendations. In: Cockett ATK, Khoury S, Aso Y et al., eds. The 2nd International Consultation on Benign Prostatic Hyperplasia (BPH). Channel Islands: Scientific Communication International Ltd., 1993: 553–564.
Neal DE Jr, Moon TD. Clinical trials of terazosin in non-bacterial prostatitis. J Urol (Part 2) 1992; 147: 231A (abstract 72).
Meares EM, Stamey TA. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol 1968; 5: 492–518.
Lepor H and Machi G. Comparison of AUA symptom index in unselected males and females between fifty-five and seventy-nine years of age. Urology 1993; 42: 36–40.
Kojima M, Naya Y, Inoue W et al. The American Urological Association symptom index for Benign Prostatic Hyperplasia as a function of age volume and ultrasonic appearance of the prostate. J Urol 1997; 157: 2160–2165.
Marks LS, Partin AW, Gormley GJ et al. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia. J Urol 1997; 157: 2171–2178.
Kaplan SA, Te AE, Jacobs BZ. Urodynamic evidence of vesical neck obstruction in men with misdiagnosed chronic non-bacterial prostatitis and the therapeutic role of endoscopic incision of the bladder neck. J Urol 1994; 152: 2063–2065.
Kaplan SA, Santarosa RP, D'Alisera PM et al. Pseudo-dyssynergia (contraction of the external sphincter during voiding) misdiagnosed as chronic non-bacterial prostatitis and the role of biofeedback as a therapeutic option. J Urol 1997; 157: 2234–2237.
Young RA, Brogden RN. Doxazosin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy mild to moderate hypertension. Drugs 1988; 35: 525–541.
Fawzy A, Braun K, Lewis GP et al. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995; 154: 105–109.
Kirby RS, Chapple CR, Christmas TJ. Doxazosin minimal blood pressure effects in normotensive BPH patients. J Urol (Part 2) 1993; 149: 434A (abstract 886).
Shapiro E, Hartanto V, Lepor H. Anti-desmin vs anti-actin for quantifying the area density of prostate smooth muscle. Prostate 1992; 20: 259–267.
Tsujii T, Azuma H, Yamaguchi T, Oshima H. A possible role of decreased relaxation mediated by α-adrenoceptors in bladder outlet obstruction by benign prostatic hyperplasia. Br J. Pharmacol 1992; 107: 803–807.
Kirby RS. Efficacy of doxazosin in normotensive and hypertensive patients with benign prostatic hyperplasia. Scand J Urol Nephrol Suppl 1995; 168: 29–33.
Lepor H, Kaplan SA, Klimberg I et al. Doxazosin for benign prostatic hyperplasia: long term efficacy and safety in hypertensive and normotensive patients. J Urol 1997; 157: 525–530.
Barbalias GA, Nikiforidis G, Liatsikos EN. α-Blockers for the treatment of chronic prostatitis in combination with anti-biotics. J Urol 1998; 159: 883–887.
Meares EM Jr. Prostatodynia: clinical findings and rationale for treatment. In: Weidner W, Brunner H, Krause W, Rothauge CF, eds. Therapy of Prostatitis. San Francisco: W. Zuckschwerdt Verlag, 1986; (11): 207–212.
Barbalias GA. Prostatodynia or painful male urethral syndrome? Urology 1990; 36: 146–153.
Lowentritt JE, Kawahara K, Human LG et al. Bacterial infection in prostatodynia. J Urol 1995; 154: 1378–1381.
Shafik A. Pudental canal syndrome: a new etiological factor in prostatodynia and its treatment by pudental decompression. Pain Dig 1998; 8: 32–38.
Neal DE, Moon TD. Use of terazosin in prostatodynia and validation of a symptom score questionnaire. Urology 1994; 43: 460–465.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Evliyaoğlu, Y., Burgut, R. Lower urinary tract symptoms, pain and quality of life assessment in chronic non-bacterial prostatitis patients treated with α-blocking agent doxazosin; versus placebo. Int Urol Nephrol 34, 351–356 (2002). https://doi.org/10.1023/A:1024487604631
Issue Date:
DOI: https://doi.org/10.1023/A:1024487604631